ARCA Biopharma (ABIO) said late Thursday that it completed its merger with Oruka Therapeutics following a stockholder approval at a special meeting on Aug. 22.
In addition, the combined company will implement a reverse stock split at a ratio of 1-for-12 shares, the company said.
The combined company will operate under Oruka Therapeutics, with shares to begin trading on a post-reverse split on Nasdaq under the ORKA ticker symbol from Sept. 3.
Price: 2.5500, Change: +0.05, Percent Change: +2.00
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。